USC Norris Comprehensive Cancer Center Keck Medicine of USC

> Keck School of Medicine of USC

Saturday, January 22, 2022 SLS Hotel, Los Angeles Hybrid Conference 7:00 am - 5:05 pm 9th Annual USC Multi-Disciplinary Breast Cancer Symposium

Presented By: USC Office of Continuing Medical Education

PROGRAM AGENDA

7:00 am	Live Registration Opens and
	Continental Breakfast
7:40 am	Virtual Login Begins
7:55 am	Welcome and Opening Remarks
	Eric L. Chang, MD, FASTRO

Session I:

Moderator: Stephen F. Sener, MD

- 8:00 am Measurement of Residual Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy Kelly K. Hunt, MD 8:35 am Ouestion and Answer
- 8:45 am Update on the Management Strategies of Breast Cancer-Related Lymphedema Ketan M. Patel, MD
- 9:20 am **Question and Answer**
- 9:30 am I-SPY 2.2: A Responsive Adaptive Trial to Prioritize Promising Investigational Agents When They Matter Most Laura Esserman, MD, MBA
- 10:05 am Question and Answer
- 10:15 am Break

Session II:

Moderator: Janice Lu, MD, PhD

 10:30 am Triple-Negative Breast Cancer: Past, Present and Future Sara M. Tolaney, MD, MPH
 11:05 am Question and Answer
 11:15 am Therapeutic Strategies Targeting HER2 Mark Pegram, MD

11:50 am Question and Answer

12:00 pm Lunch

Session III:

Moderators: Janice Lu, MD, PhD and Jason C. Ye, MD

12:50 pm	Improving Outcome for Patients with HR+ Breast Cancer. From
	Metastatic to Early Stage Disease
	Hope S. Rugo, MD
1:20 pm	Question and Answer
1:30 pm	Optimizing Therapy for Early Stage
	HER2+Breast Cancer
	Joyce O'Shaughnessy, MD
2:05 pm	Question and Answer
2:15 pm	Partial Breast Irradiation Updates
	Simona F. Shaitelman, MD, EdM
2:50 pm	Question and Answer
3:00 pm	Break

Session IV:

Moderator: Maria E. Nelson, MD

3:15 pm	Surgery for <i>de novo</i> Stage IV Breast Cancer
	Stephen F. Sener, MD
3:50 pm	Question and Answer
4:00 pm	Cases
	Jad Abdelsattar, MD, Karen Haiber, MD,
	Vera Hendrix, MD and Elizabeth Kraft, MD
4:45 pm	Question and Answer
5:00 pm	Closing Remarks
5:05 pm	Adjourn

FACULTY

PROGRAM ORGANIZING COMMITTEE

Eric L. Chang, MD, FASTRO

Professor, Chair, Course Director Department of Radiation Oncology Keck School of Medicine of USC

Stephen F. Sener, MD, FACS, FSSO

Professor of Surgery Breast, Endocrine, and Soft Tissue Surgery Division Department of Surgery Keck School of Medicine of USC Chief of Surgery LAC+USC Medical Center

Janice Lu, MD, PhD

Clinical Professor of Medicine Medical Director, Breast Oncology Program Keck School of Medicine of USC

Jason C. Ye, MD

Assistant Professor of Clinical Radiation Oncology Department of Radiation Oncology Keck School of Medicine of USC

KECK SCHOOL OF MEDICINE

Faculty Ketan M. Patel, MD

Maria E. Nelson, MD

Breast Surgical Oncologist Assistant Professor of Clinical Surgery Associate Program Director of Breast Fellowship Program

Associate Professor Director, Center for Advanced Lymphedema Treatment and Surgery Division of Plastic Surgery Department of Surgery

USC Fellows

Jad Abdelsattar, MD Karen Haiber, MD Vera Hendrix, MD Elizabeth Kraft, MD

GUEST

Faculty

Laura Esserman, MD, MBA

Director, UCSF Breast Care Center Alfred A. de Lorimier Endowed Chair in General Surgery Professor of Surgery and Radiology University of California, San Francisco San Francisco, CA

Kelly K. Hunt, MD, FACS, FSSO

Professor and Chair Department of Breast Surgical Oncology Division of Surgery The University of Texas MD Anderson Cancer Center Houston, TX

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Director, Breast Cancer Research Program Texas Oncology US Oncology Dallas, TX

Mark Pegram, MD

Susy Yuan-Huey Hung Professor of Oncology Director, Clinical and Translational Research Unit Associate Dean for Clinical Research Quality Stanford University School of Medicine Associate Director for Clinical Research Stanford Comprehensive Cancer Institute Stanford, CA

Hope S. Rugo, MD, FASCO

Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California San Francisco Medical Center Helen Diller Family Comprehensive Cancer Center San Francisco, CA

Simona F. Shaitelman, MD, EdM

Associate Professor Department of Radiation Oncology Division of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston, TX

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology Susan F. Smith Center for Women's Cancers Associate Director, Susan F. Smith Center for Women's Cancers Senior Physician Associate Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, MA

COURSE DESCRIPTION

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast pathology, surgical oncology, reconstructive surgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.

The I-SPY2 clinical trial using an adaptive design to rapidly bring forth new agents in the neoadjuvant setting has been a significant advance in trial design, presented by the principal investigator of this trial. The prognostic significance of residual burden of cancer remaining in the breast after neoadjuvant chemotherapy has assumed increasing importance in recent times and will be a featured component of this seminar. Surgical treatment of the breast in patients who present with Stage IV disease has been controversial and will be discussed in detail. Recent advances in reconstructive microsurgery will be presented by one of the internationally prominent surgeons in the field. An update in the advances in partial breast and accelerated radiation techniques will be presented.

The understanding of the HER2 receptor continues to evolve, and the biology of the HER2 axis will be presented by one of the pioneers in our understanding of this phenomenon. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.

COURSE OBJECTIVES

By the end of the course, participants will be able to:

- Understand the prognostic value of residual cancer remaining after neoadjuvant chemotherapy.
- Identify the unique features of the I-SPY2 adaptive trial design.
- Evaluate patients as candidates for oncoplastic surgical procedures and procedures to prevent and treat lymphedema after axillary operations.
- Outline the biology of the HER2 axis and its role in treating metastatic cancer.
- Describe the role of newer agents in treating metastatic ER+ cancers.
- Review newer concepts in treatment of triple negative breast cancers, including immunotherapy.
- Describe the evolving role of adjuvant partial breast radiation therapy, such as changes in dose/ fractionation and technique.
- Understand the role of surgery for patients who initially present with Stage IV disease.

TARGET AUDIENCE

This conference is designed for practicing primary care physicians, medical oncologists, radiation oncologists, surgical oncologists, radiologists, residents and fellows in oncology training programs, as well as allied health providers including oncology nurses, mid-level providers (APN and PA), radiation therapists (RTT), and any other clinicians interested or involved in the management and treatment of breast cancer.

ACCREDITATION STATEMENT

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Keck School of Medicine of the University of Southern California designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits^M. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The following may apply AMA PRA Category 1 Credit(s)[™] for license renewal: Registered Nurses may report up to 7.75 credit hour(s) toward the CME requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number. Physician's Assistants: The National Commission on Certification of Physicians' Assistants states that AMA PRA Category 1 Credits[™] accredited courses are acceptable CME requirements for recertification.

COVID-19 GUIDELINES

COVID-19 guidelines issued by the Centers for Disease Control, Los Angeles County and the University of Southern California will be strictly observed. If live attendance is discouraged as conference date approaches, registrants wll have the option of participating virtually or requesting a full refund. Proof of vaccination or negative test results 72 hours prior to live attendance will be required.

REGISTRATION FORM

	ce - Januar	iplinary Breast Cancer Symposium y 22, 2022		
Live or Virtual Tuition:	Registration closes January 22, 2022 at 9:00 am PST. Choose one: Live Attendance Virtual Attendance \$150 MD, DO \$100 NP/PA/APP \$100 NN/AH			
	🖵 \$35: Stu	dents, Residents, Fellows (Letter Needed from Program I	Director)	
Cancellation:	Cancellations must be received by the USC Office of CME (fax or email) by January 18, 12:00 pm PST for a refund. A \$50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.			
Location:	SLS Hotel, 465 S. La Cienega Boulevard, Los Angeles, CA 90048			
Parking:	Valet overnight parking \$45 and discounted day of event: \$16			
Hotel:	Rate: \$299, January 21-22, 2022. For reservations, call (310) 247-0400 before December 31, 2021.			
Register:	Mail: Online: Phone: Email:	1540 Alcazar Street, CHP 223, Los Angeles, CA 90033 Mail-in registration must be postmarked by January 18, 2 keckusc.cloud-cme.com/breastcancer2022. (213) 220-5168 I Fax: 1 (888) 665-8650 AMEX, Mastero usccme@usc.edu		
		n is available the morning of the conference until 9:00 a t keckusc.cloud-cme.com/breastcancer2022, Mastercard		
NAME		DEGREE		
MEDICAL LICENSE	NUMBER			
TELEPHONE				
TELEPHONE				
TELEPHONE ADDRESS CITY				
TELEPHONE ADDRESS CITY		STATEZIP		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_		STATEZIP		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_ INSTITUTIONAL A	FFILIATION	STATEZIP		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_ INSTITUTIONAL A *Registration confirm	FFILIATION_ ation and even	STATEZIP		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_ INSTITUTIONAL A *Registration confirm No cash payment a Check (Check p	FFILIATION_ ation and even accepted. ayable to US	STATEZIP t reminder will be emailed.		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_ INSTITUTIONAL A *Registration confirm No cash payment a O Check (Check p Credit Card (An	FFILIATION_ ation and even accepted. ayable to US nerican Expre	STATEZIP t reminder will be emailed. METHOD OF PAYMENT: C. Check payment must be postmarked by January 18, 2022)		
TELEPHONE ADDRESS CITY SPECIALTY EMAIL ADDRESS*_ INSTITUTIONAL A *Registration confirm No cash payment a Check (Check p Credit Card (An CREDIT CARD NUM	FFILIATION_ ation and even accepted. ayable to US nerican Expro MBER	STATEZIP t reminder will be emailed. METHOD OF PAYMENT: C. Check payment must be postmarked by January 18, 2022) ess by fax, Mastercard or Visa online)		